Evidence map›Paper›PMID 28256612›Full record

ArticleScientific reports2017

The role of indoleamine 2,3-dioxygenase-aryl hydrocarbon receptor pathway in the TLR4-induced tolerogenic phenotype in human DCs.

Fabián Salazar, Dennis Awuah, Ola H Negm, Farouk Shakib, Amir M Ghaemmaghami

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 66 citations in OpenAlex.

  1. Tracing NADCell reports · 2026
    Article
  2. Article
  3. Review
  4. Tracing NADResearch square · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Differences in IDO1Frontiers in immunology · 2024
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Fabián SalazarDivision of Immunology, School of Life Sciences, Faculty of Medicine and Health Sciences, University of Nottingham, United Kingdom.
Dennis AwuahDivision of Immunology, School of Life Sciences, Faculty of Medicine and Health Sciences, University of Nottingham, United Kingdom.
Ola H NegmDivision of Immunology, School of Life Sciences, Faculty of Medicine and Health Sciences, University of Nottingham, United Kingdom.
Farouk ShakibDivision of Immunology, School of Life Sciences, Faculty of Medicine and Health Sciences, University of Nottingham, United Kingdom.
Amir M GhaemmaghamiDivision of Immunology, School of Life Sciences, Faculty of Medicine and Health Sciences, University of Nottingham, United Kingdom.
University of Nottingham · GBMansoura University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A controlled inflammatory response is required for protection against infection, but persistent inflammation causes tissue damage. Dendritic cells (DCs) have a unique capacity to promote both inflammatory and anti-inflammatory processes. One key mechanism involved in DC-mediated immunosuppression is the expression of tryptophan-metabolizing enzyme indoleamine 2,3-dioxygenase (IDO). IDO has been implicated in diverse processes in health and disease but its role in endotoxin tolerance in human DCs is still controversial. Here we investigated the role of IDO in shaping DCs phenotype and function under endotoxin tolerance conditions. Our data show that TLR4 ligation in LPS-primed DCs, induced higher levels of both IDO isoforms together with the transcription factor aryl-hydrocarbon receptor (AhR), compared to unprimed controls. Additionally, LPS conditioning induced an anti-inflammatory phenotype in DCs - with an increase in IL-10 and higher expression of programmed death ligand (PD-L)1 and PD-L2 - which were partially dependent on IDO. Furthermore, we demonstrated that the AhR-IDO pathway was responsible for the preferential activation of non-canonical NF-κB pathway in LPS-conditioned DCs. These data provide new insight into the mechanisms of the TLR4-induced tolerogenic phenotype in human DCs, which can help the better understanding of processes involved in induction and resolution of chronic inflammation and tolerance.

Indexed as

B7-H1 AntigenBasic Helix-Loop-Helix ProteinsCell Adhesion MoleculesCell DifferentiationDC-Specific ICAM-3 Grabbing NonintegrinDendritic CellsGene Expression RegulationGranulocyte-Macrophage Colony-Stimulating FactorHumansImmune ToleranceIndoleamine-Pyrrole 2,3,-DioxygenaseInterleukin-10Interleukin-4Lectins, C-TypeLipopolysaccharidesMonocytesAHR protein, humanB7-H1 AntigenBasic Helix-Loop-Helix ProteinsCD274 protein, humanCell Adhesion MoleculesDC-Specific ICAM-3 Grabbing NonintegrinGranulocyte-Macrophage Colony-Stimulating FactorIDO1 protein, humanIDO2 protein, humanIL10 protein, humanIL4 protein, humanIndoleamine-Pyrrole 2,3,-DioxygenaseInterleukin-10Interleukin-4Lectins, C-TypeLipopolysaccharidesNF-kappa BNF-kappaB-Inducing KinasePDCD1LG2 protein, humanProgrammed Cell Death 1 Ligand 2 ProteinProtein Serine-Threonine KinasesReceptors, Aryl HydrocarbonReceptors, Cell SurfaceRELB protein, humanTLR4 protein, humanTNF Receptor-Associated Factor 3Toll-Like Receptor 4TRAF3 protein, humanTranscription Factor RelB

Identifiers

PMID28256612
PMCPMC5335671
OpenAlexW2594356264

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.